Logo image of MEIP

MEI PHARMA INC (MEIP) Stock Fundamental Analysis

NASDAQ:MEIP - Nasdaq - US55279B3015 - Common Stock - Currency: USD

2.705  -0.06 (-2.35%)

Fundamental Rating

4

We assign a fundamental rating of 4 out of 10 to MEIP. MEIP was compared to 572 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for MEIP as it has an excellent financial health rating, but there are worries on the profitability. While showing a medium growth rate, MEIP is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year MEIP was profitable.
MEIP had a negative operating cash flow in the past year.
In the past 5 years MEIP reported 4 times negative net income.
MEIP had negative operating cash flow in 4 of the past 5 years.
MEIP Yearly Net Income VS EBIT VS OCF VS FCFMEIP Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M -40M -60M

1.2 Ratios

With a Return On Assets value of -167.94%, MEIP is not doing good in the industry: 87.43% of the companies in the same industry are doing better.
MEIP has a Return On Equity of -187.33%. This is in the lower half of the industry: MEIP underperforms 68.32% of its industry peers.
Industry RankSector Rank
ROA -167.94%
ROE -187.33%
ROIC N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
MEIP Yearly ROA, ROE, ROICMEIP Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 50 -50 -100

1.3 Margins

MEIP does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
MEIP Yearly Profit, Operating, Gross MarginsMEIP Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -500 -1K -1.5K -2K

More info and screens

7

2. Health

2.1 Basic Checks

MEIP does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, MEIP has less shares outstanding
The number of shares outstanding for MEIP has been increased compared to 5 years ago.
MEIP has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
MEIP Yearly Shares OutstandingMEIP Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2M 4M 6M
MEIP Yearly Total Debt VS Total AssetsMEIP Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

2.2 Solvency

MEIP has an Altman-Z score of -19.60. This is a bad value and indicates that MEIP is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of MEIP (-19.60) is worse than 86.55% of its industry peers.
There is no outstanding debt for MEIP. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -19.6
ROIC/WACCN/A
WACC9.4%
MEIP Yearly LT Debt VS Equity VS FCFMEIP Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M

2.3 Liquidity

A Current Ratio of 9.66 indicates that MEIP has no problem at all paying its short term obligations.
The Current ratio of MEIP (9.66) is better than 79.82% of its industry peers.
A Quick Ratio of 9.66 indicates that MEIP has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 9.66, MEIP is in the better half of the industry, outperforming 80.00% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 9.66
Quick Ratio 9.66
MEIP Yearly Current Assets VS Current LiabilitesMEIP Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M

More info and screens

6

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 157.67% over the past year.
MEIP shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -100.00%.
MEIP shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 67.72% yearly.
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.2%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%-100%

3.2 Future

Based on estimates for the next years, MEIP will show a very negative growth in Earnings Per Share. The EPS will decrease by -67.16% on average per year.
The Revenue is expected to grow by 85.04% on average over the next years. This is a very strong growth
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%

3.3 Evolution

When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
MEIP Yearly Revenue VS EstimatesMEIP Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 1B 2B 3B
MEIP Yearly EPS VS EstimatesMEIP Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 -5 -10 -15 -20 -25

More info and screens

2

4. Valuation

4.1 Price/Earnings Ratio

MEIP is valuated cheaply with a Price/Earnings ratio of 1.01.
MEIP's Price/Earnings ratio is rather cheap when compared to the industry. MEIP is cheaper than 99.82% of the companies in the same industry.
MEIP is valuated cheaply when we compare the Price/Earnings ratio to 29.39, which is the current average of the S&P500 Index.
The Forward Price/Earnings Ratio is negative for MEIP. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 1.01
Fwd PE N/A
MEIP Price Earnings VS Forward Price EarningsMEIP Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MEIP Per share dataMEIP EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

MEIP's earnings are expected to decrease with -37.44% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for MEIP!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MEI PHARMA INC

NASDAQ:MEIP (2/11/2025, 8:00:00 PM)

2.705

-0.06 (-2.35%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-07 2024-11-07/amc
Earnings (Next)02-11 2025-02-11
Inst Owners41.05%
Inst Owner Change-64.66%
Ins Owners1.3%
Ins Owner Change0%
Market Cap18.02M
Analysts45.71
Price Target6.12 (126.25%)
Short Float %0.14%
Short Ratio0.39
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly Dividend1.75
Dividend Growth(5Y)N/A
DP-25.02%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)-10.37%
EPS NY rev (3m)-10.37%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)-100%
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE 1.01
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.72
P/tB 0.72
EV/EBITDA N/A
EPS(TTM)2.67
EY98.71%
EPS(NY)-3.78
Fwd EYN/A
FCF(TTM)-6.52
FCFYN/A
OCF(TTM)-6.52
OCFYN/A
SpS0
BVpS3.74
TBVpS3.74
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -167.94%
ROE -187.33%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-4.67%
ROA(5y)-12.05%
ROE(3y)-59.83%
ROE(5y)-64.83%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 9.66
Quick Ratio 9.66
Altman-Z -19.6
F-Score2
WACC9.4%
ROIC/WACCN/A
Cap/Depr(3y)52.51%
Cap/Depr(5y)242.29%
Cap/Sales(3y)0.42%
Cap/Sales(5y)1.3%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)157.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-114.2%
EPS Next Y-339.91%
EPS Next 2Y-84.86%
EPS Next 3Y-37.44%
EPS Next 5Y-67.16%
Revenue 1Y (TTM)-100%
Revenue growth 3Y23.34%
Revenue growth 5Y67.72%
Sales Q2Q%-100%
Revenue Next Year-100%
Revenue Next 2Y-38.12%
Revenue Next 3Y-27.39%
Revenue Next 5Y85.04%
EBIT growth 1Y-203.95%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y22.9%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y22.18%
OCF growth 3YN/A
OCF growth 5YN/A